Department of thoracic surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Research center of Antibiotic stewardship & Anti-microbial resistance, Infectious diseases department, Imam Khomeini hospital complex, Tehran University of medical sciences, Tehran, Iran.
J Cardiothorac Surg. 2023 Jul 4;18(1):211. doi: 10.1186/s13019-023-02331-0.
COVID-19 Patients may be at risk for involving with spontaneous pneumothorax. However, clinical data are lacking in this regard. In this study, we aimed to investigate the demographic, clinical, and radiological characteristics and survival predictors in COVID-19 patients with pneumothorax.
This is a retrospectivestudy conducted on COVID-19 patients with pneumothorax that had been hospitalized at hospital. l from December 2021 to March 2022. The chest computed tomography (CT) scan of all patients was reviewed by an experienced pulmonologist in search of pulmonary pneumothorax. Survival analysis was conducted to identify the predictors of survival in patients with COVID-19 and pneumothorax.
A total of 67 patients with COVID-19 and pneumothorax were identified. Of these, 40.7% were located in the left lung, 40.7% were in the right lung, and 18.6% were found bilaterally. The most common symptoms in the patient with pneumothorax were dyspnea (65.7%), increased cough severity (53.7%), chest pain (25.4%), and hemoptysis (16.4%). The frequency of pulmonary left and right bullae, pleural effusion, andfungus ball were 22.4%, 22.4%, 22.4%, and 7.5%, respectively. Pneumothorax was managed with chest drain (80.6%), chest drain and surgery (6%), and conservatively (13.4%). The 50-day mortality rate was 52.2% (35 patients). The average survival time for deceased patients was 10.06 (2.17) days.
Our results demonstrated that those with pleural effusion or pulmonary bullae have a lower survival rate. Further studies are required to investigate the incidence and causality relation between COVID-19 and pneumothorax.
COVID-19 患者可能有发生自发性气胸的风险。然而，这方面的临床数据还很缺乏。在这项研究中，我们旨在研究 COVID-19 合并气胸患者的人口统计学、临床和影像学特征及生存预测因素。
这是一项回顾性研究，纳入了 2021 年 12 月至 2022 年 3 月期间因气胸住院的 COVID-19 患者。所有患者的胸部计算机断层扫描（CT）由一名经验丰富的肺病学家进行审查，以寻找肺部气胸。进行生存分析以确定 COVID-19 合并气胸患者生存的预测因素。
共确定了 67 例 COVID-19 合并气胸患者。其中，40.7%位于左侧，40.7%位于右侧，18.6%双侧受累。气胸患者最常见的症状是呼吸困难（65.7%）、咳嗽加重（53.7%）、胸痛（25.4%）和咯血（16.4%）。肺左、右疱、胸腔积液和真菌球的发生率分别为 22.4%、22.4%、22.4%和 7.5%。气胸采用胸腔引流（80.6%）、胸腔引流和手术（6%）和保守治疗（13.4%）。50 天死亡率为 52.2%（35 例）。死亡患者的平均生存时间为 10.06（2.17）天。
我们的结果表明，有胸腔积液或肺疱的患者生存率较低。需要进一步研究以探讨 COVID-19 与气胸的发生率和因果关系。
